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52,448) for MTX, U$ 93,992 (89,36698,982) for abatacept, and $73,100 (68,539
81,877) for infliximab. The total QALYs gained(discounted) by MTX, abatacept, and
infliximab during the same period were: 2.96 (2.893.03), 4.05 (3.854.30) and 3.26
(3.163.39) respectively. The Incremental Cost-Effectiveness Ratio was U$ 39,980
(36,64945,011) for Abatacept compared to MTX compared to U$ 77,790
(62,36998,124) per QALY gained with infliximab. CONCLUSIONS: The use of
abatacept is more costeffective than the use of infliximab, both compared to
MTX, in patients with Rheumatoid Arthritis with IR MTX in Venezuela.
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OBJECTIVES: Rheumatoid Arthrtis (RA) critically impair the quality of life of pa-
tients. Biologic treatments represent a therapeutic alternative for patients who
failed disease-modifying antirheumatic drugs. However, their high cost is a chal-
lenge for clinicians and decision makers. The aim of this study was to assess the
cost-effectiveness of biologic alternatives to treat RA currently available in Mexico,
froman institutional perspective.METHODS:Adecision-treemodelwas developed
to simulate the clinical course of patients treated with etanercept (reference treat-
ment), adalimumab, infliximab, tocilizumab or rituximab as first-line therapies, as
well as associated costs over one-year period. Therapy continuation or treatment
switch was evaluated at month 6. Effectiveness measures were: proportion of pa-
tients achieving 70% improvement in both, tender or swollen joint counts following
the American College of Rheumatology (ACR70) criteria and quality adjusted life
years gained (QALY=s). Costs considered included: biologics, concomitant drugs,
medical follow-up and side effects management. Clinical response of alternatives
was extracted from published literature, while costs were collected from Instituto
Mexicano del Seguro Social (IMSS) official databases. Probabilistic sensitivity anal-
yseswere done throughMonte Carlo Simulation second-order approach. RESULTS:
The effectiveness of therapies resulted in [ACR70, QALY=s]: etanercept [31.3%, 0.79];
adalimumab [18.1%, 0.77]; infliximab [12.8%, 0.73]; tocilizumab [21.1%, 0.77] and
rituximab [11.9%, 0.75]. Expectedmean costs per patient were: US$12,914.36 [95%CI
US$12,901.58-US$12,927.08]; US$15,715.06 [95%CI US$15,699.73-US$15,730.39];
US$14,479.96 [95%CI 14,465.77-US$14,494.16]; US$44,455.03 [95%CI US$44,411.53-
US$44,498.53] and US$17,267.61 [95%CI US$17,250-US$17,284.53], respectively. Et-
anercept is both, the less costly and the most effective alternative: US$31,504.80
less than tocilizumab (the most costly alternative) and 19.3% more patients meet
the ACR70 criteria regarding rituximab (the less effective alternative). Acceptability
curves showed that etanercept regardless willingness to pay would be the most
cost-effective biologic. CONCLUSIONS: Due to their lower costs and favorable ef-
fectiveness profile, etanercept is dominant over other biologic treatments in the
management of RA at IMSS.
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OBJECTIVES: Inappropriate analgesia in postoperative pain (POP) raises hospital-
ization costs and increases the burden of several surgeries with a meaningful im-
pact over patient’s quality of life. The objective of this study was to develop an
economic analysis to evaluate parecoxib, ketorolac andmorphine in the treatment
of POP in patients who underwent total hip arthroplasty from an institutional
perspective. METHODS: A cost-effectiveness analysis was developed using a
Bayesian decision-tree model, to simulate costs and effectiveness outcomes over
the postoperative hospitalization period (15 days). Comparators were multimodal
analgesics: morphine (52 mg/day) plus parecoxib (40 mg/day); morphine (52 mg/
day) plus ketorolac (90 mg/day) and morphine (57 mg/day) alone. Effectiveness
measures were: percentage of treatment response without adverse events (AE)
meeting the highest score of the patient’s global evaluation survey (excellent).
Effectiveness data and transition probabilities were collected from international
published literature. Resource use and cost data was gathered from hospital re-
cords of patients undergoing total hip arthroplasty at the Social Security Mexican
Institute (IMSS) (n89). The model was calibrated according to international phar-
macoeconomics guidelines. One-way and probabilistic sensitivity analyses were
performed with Monte Carlo Simulation second-order approach. RESULTS: Pa-
tients who received parecoxib exhibited 41% of treatment response, followed by
morphine (26%) and ketorolac (24%). Estimated costs per patient were lower with
parecoxib (US$ 5,439.30) followed by ketorolac (US$5,538.91) and morphine
(US$5,553.71). No statistical differences were found among the costs of analgesic
therapies (p0.05). Parecoxib showed a weak dominance against its competitors.
Acceptability curves showed parecoxib as themost cost-effective therapywith 95%
when willingness to pay is US$6,500. CONCLUSIONS: Results show that at the
IMSS, parecoxib is a cost-effective treatment that significantly reduces POP in pa-
tients who underwent total hip arthropasty. This information could be useful for
developing markets healthcare institutions in order to establish efficient analge-
sics improving current health outcomes.
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OBJECTIVES: The goal of this studywas to estimate the cost-effectiveness of stron-
tium ranelate in the treatment of postmenopausal osteoporotic women in Turkey.
METHODS: A validated Markov microsimulation model with a Turkish payer’s
perspective estimated the cost per quality-adjusted life-year (QALY) of strontium
ranelate treatment compared with risedronate, raloxifene, ibandronate, alendro-
nate and calcitonin. Markov Model was used and applied in the Treeage Pro soft-
ware over a cohort of 1000 patients in the pharmacoeconomical analysis. As for the
sensitivity analysis, theMonte Carlo Simulationwas used, applying a simulation of
10.000. Data on the effect of both treatments on fracture risk were taken from the
literature. The cost of the treatments were calculated based on Turkish reimburse-
ment systems, the indirect and intangible costs were omitted. The direct disease
costs include the amount spent for the costs associated with the outpatient, inpa-
tient, medical supplies, all the laboratory or imaging tests and the interventions
performed. The costs of the side effectswere added to all the drug costs. The official
product summaries were used for detecting the side effects of the products.
RESULTS: Strontium Ranelate provides the highest gain of quality life years and is
the superlative therapeutical choice with respect to QALY. According to it’s cost
and effectiveness value, strontium ranelate was dominant (i.e. more effective and
less costly) versus ibandronate and calcitonine for postmenopausal osteoporotic
women. The cost per QALY gained by strontium ranelate compared to ibandronate
was € 5582 and calcitonine was € 3943. Compared to alendronate, risedronate and
raloxifene, strontium ranelate was cost effective (i.e. more costly but more
effective).CONCLUSIONS:The results of this study suggest that strontium ranelate
is a cost-effective strategy, in a Turkish setting, for the treatment of postmeno-
pausal osteoporotic women.
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OBJECTIVES: Determine the costeffectiveness of abatacept or infliximab in pa-
tients with rheumatoid arthritis (RA) with inadequate response to methotrexate
(IRMTX) in Colombia. METHODS: Dynamic simulation techniques from a previ-
ously validatedmodel and clinical data from published literature were used for the
analysis. The functional disability was assessed using the Health Assessment
Questionnaire (HAQ). A HAQ score was randomly assigned pretreatment based
on the prevalence of the disease and the demographic characteristics for Colombia,
then projected over time using the efficacy results from published trials. Direct
medical costs were calculated from private and public hospitals,and the informa-
tion system of the Ministry of Social Protection (SISMED) and validated with local
experts (Exchange rate: $1,920 Colombian peso1 US Dollar). A 10year time ho-
rizon and the payer’s perspective were assumed. Costs and health outcomes were
discounted at 3% annually. Univariate and probabilistic sensitivity analyses were
performed to assess the robustness of the results of the model. RESULTS: In a
hypothetical cohort of 1,000 patients with RA  IR MTX, the costs of treatmentfor
the first year for MTX were U$794 dollars, compared to U$16,659 for abatacept and
U$17,531 for infliximab, assuming dosages for average patients below 60 kg. Addi-
tional analysis with patients over 60 kg were included in the sensitivity analysis.
After 10 years of followup the discounted total direct medical costs per patient
were U$55,998 (54,35457,776) for MTX, U$99,888 (94,694104,437) for abatacept,
and $79,174 (75,79583,899)for infliximab. The total number of QALYs gained (dis-
counted) by MTX, abatacept, and infliximab were: 2.88 (2.792.95), 3.94 (3.794.09)
and 3.17 (3.093.27) respectively. The calculated ICERs for abatacept and infliximab
compared to MTX were U$ 37,513 (35,22139,909) and U$75,873 (62,825103,132)
per QALY gained, respectively. CONCLUSIONS: In patients with RA  IR MTX in
Colombia, the use of abatacept is more cost-effective than the use of infliximab,
both compared to MTX.
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OBJECTIVES: To conduct a structured review of the recent osteoporosis cost-effec-
tiveness modeling literature and provide an overview of their methodologies and
approaches.METHODS:A detailed systematic reviewwas performed of the follow-
ing literature databases: MEDLINE, MEDLINE In-Process, EMBASE, Cochrane, HEED,
NHSEED, EconLit, and googlescholar. Using pre-selected inclusion/exclusion crite-
ria relevant studies published since January 2005 were identified. Relevant infor-
mation fromeach identified studywas extracted according to a predefined grid and
essential features of each osteoporosis cost-effectiveness model were recorded.
RESULTS: Forty-eight relevant and recently published osteoporosis cost-effective-
ness models were identified. Model structures were cohort Markov (56%) and indi-
vidualized microsimulations (44%). Most models (35) used a lifetime timeframe
(i.e., death or age 100). The primary interventions investigated were bisphospho-
nates (79%), raloxefine (15%), and hormone replacement therapy (10%). In 98% of
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the models hip fracture was a specific outcome, 94% contained vertebral fractures,
and 77% containedwrist/forearm fractures. Elevenmodels incorporate at least one
extraskeletal effect on cost and survival (including breast cancer, coronary heart
disease, venous thromboembolism, stroke, and colorectal cancer). Thirty-two (32)
of the 48 publications (67%) assume 100% compliance or do not directly mention/
model compliance. The majority of the models take the approach that there was
discontinuation and non-compliance in the clinical trials, and that the treatment
efficacy rates sourced from the clinical trials are underestimated due to the use of
an intention-to-treat paradigm. CONCLUSIONS: The current state of osteoporosis
modeling favors a non-cohort Markov approach, with individualized, i.e., micro-
simulation methodology being increasingly utilized as extraskeletal effects are
incorporated. Treatment compliance and extraskeletal effects are extremely im-
portant in modeling real-world scenarios, yet they are not incorporated into the
majority of the published models. Modeled treatment effectiveness should be
properly imputed to account for the intention-to-treat impact of RCT-reported
values as well as the reduced benefits of treatment noncompliance.
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OBJECTIVES: Because of its prevalent condition and its association with hip frac-
tures in the elderly population, Osteoporosis has become a major concern for
health authorities in recent years. The objective of this study is to evaluate the
most cost-effective alternative for preventing hip fractures in osteoporosis patients
in Mexico. METHODS: A cost-effectiveness analysis was performed within an insti-
tutional setting (Mexican Institute of Social Security, IMSS). Patients were categorized
into 2 groups by age: group A was comprised with patients ages 60 to 79 years, and
groupBwascomprisedwithpatientsaged80years.Thestandardof carecomparator
usedwasall biphosphonates available in theNational Formulary: risedronate, original
alendronate, generic alendronate, and ibandronate. Resource use data was obtained
frompublished studies; total direct costs of osteoporosis and hip fractures were used.
The source of the unit costs was the institution, current for 2006. All costs are ex-
pressed in local currency (Mexican Pesos, MXP). The time horizon was 10 years; a
discount rate of 3%wasused. Effectiveness datawas obtained frompublished studies;
themeasureusedwaship fractures prevented. Aprobabilistic sensitivity analysiswas
obtained through a Monte Carlo simulation with 100,000 iterations in the weakest
parameters. RESULTS: In both groups, zoledronic acid was the most cost-effective
treatment. In group A, the C/E ratio was $221.43 MXP, as compared with $270.77 for
generic alendronate, $332.50 for ibandronate, $340.24 for risedronate and $353.32
for original ibandronate. Likewise, in group B the C/E ratio for zoledronic acid was
$574.50, as compared to $799.77 for generic alendronate, $941.52 for ibandronate,
$961.38 for risedronate, and $993.89 for original alendronate. The sensitivity anal-
ysis confirmed the robustness of the model. CONCLUSIONS: From an institutional
perspective, zoledronic acid is themost cost-effective alternative for the prevention of
hip fractures in patients with osteoporosis in Mexico.
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OBJECTIVES: High costs of rheumatoid arthritis (RA) and osteoarthritis (OA) due
not only to high morbidity, disability and mortality levels, but also basis medica-
tions and treatment of adverse events which are very expensive. METHODS: We
analyzed the efficacy and safety data from randomized clinical trials and system-
atic reviews of symptomatic treatment OA and RA patients with meloxicam and
diclofenac. We were searching data on: www.cochrane.org, www.pubmed.gov,
www.clinicaltrials.gov. Amodel “decision tree”was built based on two information
sources: 1) literature review; 2) cost databases. We calculate the average direct
costs of one serious cardiovascular thromboembolic adverse event and one serious
gastrointestinal adverse event in Ukraine. We determined the CER based on costs
from our “decision tree”model and data from the IMPROVE study. RESULTS:Direct
costs of one serious cardiovascular and gastrointestinal adverse event were
USD$590.29 andUSD$613.81 (1 USD$ 7.95UAHon 10.01.2011), respectively. Direct
costs of 60 days symptomatic treatment of 100 RA or OA patients with meloxicam
7.5 mg daily and diclofenac 100 mg daily were USD$2057.99 and USD$4975.22,
respectively. CERmeloxicamwas calculated 30.72 and CER diclofenac - 117.34. The
one-way sensitivity analysis performedwith themost relevant varables confirmed
this tendency. CONCLUSIONS: Results show that Meloxicam 7.5 daily is more eco-
nomical effective versus diclofenac 100 mg daily for symptomatic treatment of RA
and OA patients taking into account probability of serious cardiovascular trombo-
embolic and gastrointestinal adverse events.
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OBJECTIVES: To assess the cost-effectiveness of limited fasciectomy (LF), percuta-
neous needle fasciotomy (PNF), and collagenase clostridiumhistolyticum (CCH) for
the treatment of Dupuytren’s contracture.METHODS: AMarkov model was devel-
oped to simulate Dupuytren’s contracture progression and estimate clinical/eco-
nomic implications of LF, PNF, and CCH treatments from a US healthcare payer
perspective. Transition probabilities were assumed to follow a beta distribution
and were estimated based on results from randomized, clinical trials. Health state
utilities and direct costs of therapies were assumed to follow a gamma distribution
and obtained from published sources. Half-cycle correction was used with a 1-year
cycle length over a 10-year time horizon. One-way sensitivity analyses were per-
formed on relevant variables to test the robustness of the model. Probabilistic
sensitivity analysis was performed using 10,000 trial simulations for all variables
and results were presented as acceptability curves. Themodel used a discount rate
of 3% per annum and reported in 2010 $US dollars. Primary outcomes evaluated
incremental cost-effectiveness ratios. RESULTS: Of the 3 treatment decisions, LF
was the dominant strategy. PNF and CCH were estimated to cost an additional
$247 and $1844 compared to LF, respectively. An expected difference of0.1 and
0.04 quality-adjusted life years (QALYs) were projected for PNF and CCH rela-
tive to LF, respectively. In the one-way sensitivity analysis, the model was sen-
sitive to direct cost of LF with a break-even point of $2000 compared to PNF. The
acceptability curve showed that LF had a higher probability of being cost-effec-
tive compared to other treatment modalities across a WTP threshold of $0 to
$500,000. CONCLUSIONS:Across aWTP threshold between $0 and $500,000, LFwas
themost cost-effective therapy for the treatment of Dupuytren’s contracture com-
pared to PNF and CCH. However, the cost of surgery was sensitive in our model
which may vary from site to site.
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OBJECTIVES: To estimate the cost-effectiveness of denosumab vs. the most com-
monly used therapy (alendronatecolecalciferol) in treatment of post-menopausal
osteoporosis (PMO) in Portugal. METHODS: A Markov cost-utility life-cycle model
with six month cycle length was used. The analysis was undertaken from a Na-
tional Health Service (NHS) perspective. Efficacy data for denosumab was taken
from the FREEDOM randomized double-blind clinical trial and for the comparator
from a meta-analysis conducted by NICE. Epidemiological data were derived from
Portuguese sources and complemented with Swedish data whenever the former
were unavailable. Resource use data were collected through a modified Delphi
panel of Portuguese experts (including rheumatologists, GPs and orthopedic sur-
geons). Resources were valued using various national sources on unit costs. EQ-5D
decrements per fracture were based on the international literature. Expected per-
sistence differences between treatments were also considered. Deterministic sen-
sitivity analysis was conducted on key variables (including costs, utilities, impact
of fractures on mortality, non-inclusion of sub-optimal persistence, comparator’s
price, age and T-score for treatment initiation). Probabilistic sensitivity analysis
was performed on the model’s treatment effects, fracture costs, EQ-5D fracture
decrements and persistence rate differences. RESULTS: Considering an annual
NHS cost of €382.20 for denosumab, the estimated ICER was €14,487 per QALY
gained. The model predicts that, relative to the comparator, denosumab would
prevent 12 hip, 22 vertebral, 2 wrist and 1 other osteoporotic fractures, per 1000
patients, over a 10 year period. Deterministic sensitivity analysis identified the
absence of a persistence effect and the use of generic alendronate price as themost
sensitive parameters (22,906, 20,817 €/QALY, respectively). The probability of cost-
effectiveness ranged between 91% and 64% (willingness to pay set at 50,000 and
20,000 €/QALY, respectively). CONCLUSIONS: Results from the model suggest that,
compared to the most commonly used strategy (alendronatecolecalciferol), de-
nosumab is a cost-effective therapy in the treatment of PMO in Portugal.
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OBJECTIVES: A major challenge facing policy makers is the lack of economic evi-
dence to guide their decisions about allocating health services for neck pain. Our
objective was to evaluate the cost-effectiveness of the most commonly used neck
pain treatments in Canada and the United States. METHODS: We conducted a
cost-utility analysis with a decision-analytic model of 5 treatments for neck pain
(exercise, cyclooxegenase-2 selective inhibitors, manipulation, mobilization, and
nonsteroidal anti-inflammatory drugs [NSAIDs]) using a lifetime time horizon and
adopting a health care system perspective. Model inputs included: estimates of the
course of neck pain; background risk of adverse events in the general population;
treatment effectiveness and risk of cerebrovascular, cardiovascular, and gastroin-
testinal adverse events; quality-of-life weights elicited from neck pain patients
using the standard gamble; and direct and out-of-pocket costs. Costs were ex-
pressed in 2008 Canadian prices. The impact of beneficial and harmful treatment
effects on health were expressed in quality-adjusted life years (QALYs). Cost-effec-
tiveness was estimated with the incremental cost-effectiveness ratio (ICER). The
probability that a given treatment was cost-effective was determined using a will-
ingness-to-pay (WTP) threshold of $50,000 per QALY. RESULTS: Under a conven-
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